How long can carpisetin/Tsuncote prolong the survival of patients?

Capivasertib is an oral small molecule AKT inhibitor, a targeted therapy drug, mainly used to treat breast cancer and other solid tumors related to PI3K/AKT pathway activation. The AKT signaling pathway is abnormally activated in a variety of tumors and is an important mechanism for tumor cell proliferation, survival, and drug resistance. By inhibiting AKT activity, carpisetin can inhibit tumor cell proliferation, promote apoptosis, and enhance the efficacy of other chemotherapy or targeted drugs, thereby providing potential survival benefits for patients.

Current clinical studies and overseas reports show that carpiseti can significantly delay disease progression, improve progression-free survival (PFS), and improve overall survival (OS) to a certain extent in breast cancer patients treated with endocrine therapy or other targeted drugs. Although the specific prolongation time varies depending on individual patient differences, disease type and previous treatment history, in the patient group verified by clinical trials, carpisetin provides new treatment hope for refractory breast cancer. Compared with traditional chemotherapy, treatment options targeting the AKT pathway can achieve more precise intervention, delay tumor progression, and reduce the impact of drug side effects on quality of life.

It is worth noting that the specific time of prolonged survival is not only affected by the efficacy of the drug itself, but also closely related to the patient's overall health status, tumor burden, concomitant medication, and treatment compliance. When formulating a treatment plan, doctors will take into account the patient's pathological type, genetic test results, previous treatment history and tolerance to reasonably evaluate the expected efficacy of carpisetin. During the course of treatment, patients should be closely followed up, including regular imaging evaluation, hematological and biochemical index monitoring, so that the dosage and treatment course can be adjusted in a timely manner to maximize drug benefits.

Reference materials:https://www.drugs.com/mtm/capivasertib.html